Daridorexant, a dual orexin receptor antagonist, is currently approved for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

The recommendations were made following a meeting that included experts from the FDA, the Centers for Disease Control and Prevention, and the Department of Defense.

The Food and Drug Administration (FDA) has approved Iluvien® (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious ...

First Xolair biosimilar approved; wearable furosemide delivery system gains expanded indication; implant approved for macular telangiectasia; novel treatment shows promise in hypertension; and testing ...

HealthDay News — For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8mg is efficacious and tolerable, according to a study ...

HealthDay News — Although most manufacturer reports of medical device adverse events are reported on time, a considerable proportion are submitted late, according to a study published online March 12 ...

HealthDay News — Short sleep (<7.7 hours) among adolescents is associated with elevated blood pressure (systolic ≥120mmHg and diastolic <80mmHg), according to a study presented at the American Heart ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

Topline data were announced from a phase 2/3 trial evaluating Flebogamma 5% DIF (immune globulin intravenous ) in patients with post-polio syndrome (PPS).

In a survey, most providers in a large integrated health system said they accepted billing for e-visits and indicated that it took little to no effort to complete.